The Orexin-1 receptor is considered to be central to the brain’s “craving” and “reward” pathways with pre-clinical efficacy observed in multiple addiction models. Prior to the licensing deal with Indivior, C4XD had demonstrated that C4X_3256 attenuated cocaine-induced brain dopamine elevation supporting its potential in this important therapeutic area and adding to the compelling pre-clinical efficacy data already achieved in nicotine addiction showing reductions in self-administration and re-instatement.
In July 2018 C4XD was delighted to announce
that the C4X_3256 programme had been awarded a grant from the National Institute on Drug Abuse (“NIDA”, a division of National Institute of Health (“NIH”)). The grant of approximately $480k
will support the investigation of the effects of C4X_3256 in cocaine addiction efficacy models extending the pre-clinical pharmacology package in parallel with clinical development.